EP2566880A4 - AROMATIC-CATIONIC PEPTIDES AND THEIR APPLICATIONS - Google Patents

AROMATIC-CATIONIC PEPTIDES AND THEIR APPLICATIONS

Info

Publication number
EP2566880A4
EP2566880A4 EP11778123.7A EP11778123A EP2566880A4 EP 2566880 A4 EP2566880 A4 EP 2566880A4 EP 11778123 A EP11778123 A EP 11778123A EP 2566880 A4 EP2566880 A4 EP 2566880A4
Authority
EP
European Patent Office
Prior art keywords
aromatic
applications
cationic peptides
peptides
cationic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11778123.7A
Other languages
German (de)
French (fr)
Other versions
EP2566880A1 (en
Inventor
Liping Liu
Lawrence Gu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Peptides International Inc
Original Assignee
Stealth Peptides International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides International Inc filed Critical Stealth Peptides International Inc
Priority to EP16168791.8A priority Critical patent/EP3130599A1/en
Priority to EP18193073.6A priority patent/EP3450447A1/en
Priority to EP17184810.4A priority patent/EP3290433A1/en
Priority to EP15160602.7A priority patent/EP2942354A1/en
Publication of EP2566880A1 publication Critical patent/EP2566880A1/en
Publication of EP2566880A4 publication Critical patent/EP2566880A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/0027—Methods for using particle spectrometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
EP11778123.7A 2010-05-03 2011-05-02 AROMATIC-CATIONIC PEPTIDES AND THEIR APPLICATIONS Withdrawn EP2566880A4 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP16168791.8A EP3130599A1 (en) 2010-05-03 2011-05-02 Aromatic-cationic peptides and uses of same
EP18193073.6A EP3450447A1 (en) 2010-05-03 2011-05-02 Aromatic-cationic peptides and uses of same
EP17184810.4A EP3290433A1 (en) 2010-05-03 2011-05-02 Aromatic-cationic peptides and uses of same
EP15160602.7A EP2942354A1 (en) 2010-05-03 2011-05-02 Aromatic-Cationic Peptides and Uses of Same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33046010P 2010-05-03 2010-05-03
PCT/US2011/034846 WO2011139992A1 (en) 2010-05-03 2011-05-02 Aromatic-cationic peptides and uses of same

Related Child Applications (4)

Application Number Title Priority Date Filing Date
EP16168791.8A Division EP3130599A1 (en) 2010-05-03 2011-05-02 Aromatic-cationic peptides and uses of same
EP17184810.4A Division EP3290433A1 (en) 2010-05-03 2011-05-02 Aromatic-cationic peptides and uses of same
EP15160602.7A Division EP2942354A1 (en) 2010-05-03 2011-05-02 Aromatic-Cationic Peptides and Uses of Same
EP18193073.6A Division EP3450447A1 (en) 2010-05-03 2011-05-02 Aromatic-cationic peptides and uses of same

Publications (2)

Publication Number Publication Date
EP2566880A1 EP2566880A1 (en) 2013-03-13
EP2566880A4 true EP2566880A4 (en) 2014-10-08

Family

ID=44904014

Family Applications (5)

Application Number Title Priority Date Filing Date
EP17184810.4A Withdrawn EP3290433A1 (en) 2010-05-03 2011-05-02 Aromatic-cationic peptides and uses of same
EP11778123.7A Withdrawn EP2566880A4 (en) 2010-05-03 2011-05-02 AROMATIC-CATIONIC PEPTIDES AND THEIR APPLICATIONS
EP15160602.7A Withdrawn EP2942354A1 (en) 2010-05-03 2011-05-02 Aromatic-Cationic Peptides and Uses of Same
EP18193073.6A Withdrawn EP3450447A1 (en) 2010-05-03 2011-05-02 Aromatic-cationic peptides and uses of same
EP16168791.8A Withdrawn EP3130599A1 (en) 2010-05-03 2011-05-02 Aromatic-cationic peptides and uses of same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP17184810.4A Withdrawn EP3290433A1 (en) 2010-05-03 2011-05-02 Aromatic-cationic peptides and uses of same

Family Applications After (3)

Application Number Title Priority Date Filing Date
EP15160602.7A Withdrawn EP2942354A1 (en) 2010-05-03 2011-05-02 Aromatic-Cationic Peptides and Uses of Same
EP18193073.6A Withdrawn EP3450447A1 (en) 2010-05-03 2011-05-02 Aromatic-cationic peptides and uses of same
EP16168791.8A Withdrawn EP3130599A1 (en) 2010-05-03 2011-05-02 Aromatic-cationic peptides and uses of same

Country Status (4)

Country Link
US (6) US20130059799A1 (en)
EP (5) EP3290433A1 (en)
JP (3) JP2013532124A (en)
WO (1) WO2011139992A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2964555T3 (en) 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Peptide for use in the prevention or treatment of macular degeneration
EP2788013A4 (en) * 2011-12-09 2015-08-19 Stealth Peptides Int Inc Aromatic-cationic peptides and uses of same
CN105753939A (en) * 2012-04-12 2016-07-13 康德生物医疗技术公司 Aromatic-cationic Peptides And Uses Of Same
ES2755134T3 (en) 2013-03-01 2020-04-21 Stealth Biotherapeutics Corp Methods for treating mitochondrial disease
US9687519B2 (en) 2013-03-01 2017-06-27 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
JP2016539931A (en) * 2013-10-23 2016-12-22 株式会社カネカ Tetrapeptide compound and method for producing the same
CA2976632A1 (en) * 2015-02-13 2016-08-18 Stealth Biotherapeutics Corp Therapeutic compositions including mitochondrial fission inhibitor peptides, variants thereof and methods of using the same
EP3265109B1 (en) * 2015-03-06 2020-10-21 Stealth BioTherapeutics Corp Processes for preparing pharmaceutically relevant peptides
WO2017180535A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
ES2942631T3 (en) * 2017-12-15 2023-06-05 Stealth Biotherapeutics Inc Peptides targeting mitochondria
CN108982712A (en) * 2018-10-08 2018-12-11 山东越品检验检测有限公司 Salmeterol, datro, the method for Ao Dateluo in a kind of measurement pork
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US12269315B2 (en) 2020-08-20 2025-04-08 Denso International America, Inc. Systems and methods for measuring and managing odor brought into rental vehicles
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US12377711B2 (en) 2020-08-20 2025-08-05 Denso International America, Inc. Vehicle feature control systems and methods based on smoking
US12251991B2 (en) 2020-08-20 2025-03-18 Denso International America, Inc. Humidity control for olfaction sensors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DK72587D0 (en) * 1987-02-13 1987-02-13 Carlsberg Biotechnology Ltd PROCEDURE FOR ENZYMATIC DIPEPTID PREPARATION
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
EP1599216B9 (en) * 2003-02-04 2015-02-11 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
PL2604286T3 (en) * 2003-05-01 2015-03-31 Cornell Res Foundation Inc Method and Carrier Complexes for Delivering Molecules to Cells
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP3741381B1 (en) * 2008-02-26 2024-04-24 Cornell University A peptide for use for prevention and treatment of acute renal injury
GB0805912D0 (en) * 2008-04-01 2008-05-07 Bioalvo Servi Os Investiga Oo Treatment
GB0805862D0 (en) * 2008-04-01 2008-04-30 Bioalvo Servi Os Investiga Oo Method
US20100331265A1 (en) * 2009-03-20 2010-12-30 Tompkins Ronald G Methods for the prevention and treatment of burn injuries and secondary complications
CA2787331A1 (en) * 2010-01-25 2011-07-28 Hazel H. Szeto Aromatic-cationic peptides and uses of same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
US20190106458A1 (en) 2019-04-11
US20160376309A1 (en) 2016-12-29
US20250051389A1 (en) 2025-02-13
JP2018111710A (en) 2018-07-19
US20150065437A1 (en) 2015-03-05
EP3450447A1 (en) 2019-03-06
EP3130599A1 (en) 2017-02-15
JP2017061457A (en) 2017-03-30
EP2942354A1 (en) 2015-11-11
WO2011139992A1 (en) 2011-11-10
EP2566880A1 (en) 2013-03-13
US20130059799A1 (en) 2013-03-07
EP3290433A1 (en) 2018-03-07
JP2013532124A (en) 2013-08-15
US20210130402A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
EP2566880A4 (en) AROMATIC-CATIONIC PEPTIDES AND THEIR APPLICATIONS
CY2025026I2 (en) HUMAN ANTI-TISSUE FACTOR ANTI-ANTIBODY-DRUG CONJUGATES
EP2768516A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
DK2920197T3 (en) PROLINE-LOCKED STOPPED PEPTIDES AND USES THEREOF
DK2552434T3 (en) PEPTIDES AND USE THEREOF
DK3339323T3 (en) ANTI-N3PGLU-AMYLOID-BETA-PEPTIDE ANTIBODIES AND APPLICATIONS THEREOF
CO7020851A2 (en) Proteins and modified peptides
EP2593469A4 (en) MODIFIED PROTEINS AND POLYPEPTIDES AND USES THEREOF
EP2817021A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
DK3346008T3 (en) Recombinant microorganisms and their uses
EP2605789A4 (en) MODIFIED RELAXINE POLYPEPTIDES AND USES THEREOF
IL225187A0 (en) Immunoglobulin carriers and their uses
IL232247B (en) Polypeptide structures and their uses
EP2688579A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
BR112014009050A2 (en) pyrrolbenzodiazepines and conjugates thereof
EP2542221A4 (en) PROTEIN CONCENTRATED FORMULATIONS AND USES THEREOF
EP2639896A4 (en) CONNECTOR AND SWITCH
PL2580240T3 (en) S100A4 ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
BR112013011340A2 (en) gels and hydro gels
IL237135B (en) Peptide library and their uses
EP2593595A4 (en) Novel peptides and uses thereof
DK2704744T3 (en) COMPLEMENT FACTOR B-ANALOGS AND USES THEREOF
IL229926A (en) 3neil peptides and vaccines containing them
BR112013024323A2 (en) neuroprotective peptides
PL2627668T3 (en) Peptides and uses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1183310

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20140909

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 5/087 20060101ALI20140903BHEP

Ipc: A61P 9/10 20060101ALI20140903BHEP

Ipc: C07K 5/103 20060101ALI20140903BHEP

Ipc: A61P 3/00 20060101ALI20140903BHEP

Ipc: A61P 25/28 20060101ALI20140903BHEP

Ipc: A61K 38/05 20060101ALI20140903BHEP

Ipc: A61K 38/06 20060101ALI20140903BHEP

Ipc: C07K 5/107 20060101ALI20140903BHEP

Ipc: C07K 5/068 20060101ALI20140903BHEP

Ipc: A61P 5/50 20060101ALI20140903BHEP

Ipc: A61P 25/16 20060101ALI20140903BHEP

Ipc: C07K 5/09 20060101ALI20140903BHEP

Ipc: A61K 38/07 20060101ALI20140903BHEP

Ipc: C07K 5/065 20060101ALI20140903BHEP

Ipc: C07K 5/11 20060101AFI20140903BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150408

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1183310

Country of ref document: HK